Particulate Vaccine Dispersions Emerge as a Novel Carrier for Deep Pulmonary Immunization DOI
Dilpreet Singh, Prashant Tiwari, Sanjay Nagdev

et al.

Current Nanomedicine, Journal Year: 2023, Volume and Issue: 13(2), P. 71 - 74

Published: July 1, 2023

Language: Английский

Recent Developments in Aerosol Pulmonary Drug Delivery: New Technologies, New Cargos, and New Targets DOI
Ian R. Woodward, Catherine A. Fromen

Annual Review of Biomedical Engineering, Journal Year: 2024, Volume and Issue: 26(1), P. 307 - 330

Published: March 1, 2024

There is nothing like a global pandemic to motivate the need for improved respiratory treatments and mucosal vaccines. Stimulated by COVID-19 pandemic, pulmonary aerosol drug delivery has seen flourish of activity, building on prior decades innovation in particle engineering, inhaler device technologies, clinical understanding. As such, field expanded into new directions working toward efficient increasingly complex cargos address wider range diseases. This review seeks highlight recent innovations approaches personalize inhalation delivery, deliver cargos, diversify targets treated prevented through delivery. We aim inform readers emerging efforts within predict where future breakthroughs are expected impact treatment

Language: Английский

Citations

7
The role of engineered materials in mucosal vaccination strategies DOI
Behnaz Eshaghi,

Alex Schudel,

Ilin Sadeghi

et al.

Nature Reviews Materials, Journal Year: 2023, Volume and Issue: 9(1), P. 29 - 45

Published: Dec. 18, 2023

Language: Английский

Citations

13
On the path to predicting immune responses in the lung: Modeling the pulmonary innate immune system at the air-liquid interface (ALI) DOI Creative Commons

Jodi Graf,

Michael Trautmann-Rodriguez,

Simone Sabnis

et al.

European Journal of Pharmaceutical Sciences, Journal Year: 2023, Volume and Issue: 191, P. 106596 - 106596

Published: Sept. 26, 2023

Chronic respiratory diseases and infections are among the largest contributors to death globally, many of which still have no cure, including chronic obstructive pulmonary disorder, idiopathic fibrosis, syncytial virus others. Pulmonary therapeutics afford untapped potential for treating lung infection disease through direct delivery site action. However, ability innovate new therapeutic paradigms will rely on modeling human microenvironment key cellular interactions that drive disease. One feature is air-liquid interface (ALI). ALI techniques, using cell-culture inserts, organoids, microfluidics, precision slices (PCLS), rapidly developing; however, one major component these models lacking—innate immune cell populations. Macrophages, neutrophils, dendritic cells, others, represent populations, acting as first responders during or injury. Innate cells respond modulate stromal bridge gap between innate adaptive system, controlling bodies response foreign pathogens debris. In this article, we review current state culture systems with a focus suggest ways build add complexity relevant

Language: Английский

Citations

11
Hydrogen-induced disruption of the airway mucus barrier enhances nebulized RNA delivery to reverse pulmonary fibrosis DOI Creative Commons
Chang Liu,

Xidong Tian,

Zhenping Wang

et al.

Science Advances, Journal Year: 2025, Volume and Issue: 11(16)

Published: April 16, 2025

Nebulized RNA therapies are well suited for treating respiratory diseases, in particular pulmonary fibrosis (PF); however, effective delivery remains challenging. In this study, we present a highly efficient aerosol inhalation system that enables high levels of vivo transfection efficiency lung macrophages, yielding durable responses against PF. First, established nose-only device integrated with hydrogen supplement system. This setup the precise administration lipid nanoparticles (LNPs) at controlled low dose, while simultaneously delivering optimal concentration therapeutic gas. We further developed hybrid NP (HNP) by hybridizing pH-dependent charge-inverting film apoptotic T cell membranes to enhance endosomal escape and trigger macrophage production hepatocyte growth factor repair. demonstrated flow–induced shear stresses disrupt NP-mucus interaction, enhancing deposition aerosolized HNPs/ TGF β 1 siRNA within fibrotic lesions, effectively blocking fibrogenic signaling pathways offering clinically viable strategy combating

Language: Английский

Citations

0
Air Pollution, Nanomaterials, and Bioremediation DOI
Sherif Edris

Published: Jan. 1, 2025

Language: Английский

Citations

0
Engineering porous PLGA microparticles for pulmonary delivery of sildenafil citrate DOI
Raul Edison Luna Lazo,

Bruna de Paula Oliveira,

Alexandre de Fátima Cobre

et al.

Powder Technology, Journal Year: 2023, Volume and Issue: 430, P. 118999 - 118999

Published: Sept. 22, 2023

Language: Английский

Citations

9
Quality by Design in Pulmonary Drug Delivery: A Review on Dry Powder Inhaler Development, Nanotherapy Approaches, and Regulatory Considerations DOI

Ashish Dilip Sutar,

Rahul Kumar Verma, Rahul Shukla

et al.

AAPS PharmSciTech, Journal Year: 2024, Volume and Issue: 25(6)

Published: Aug. 2, 2024

Language: Английский

Citations

3
Nanotechnology of inhalable vaccines for enhancing mucosal immunity DOI
Qin Li,

Yanhua Sun,

Nan Gao

et al.

Drug Delivery and Translational Research, Journal Year: 2023, Volume and Issue: 14(3), P. 597 - 620

Published: Sept. 25, 2023

Language: Английский

Citations

6
Reshaping respiratory care: potential advances in inhaled pharmacotherapy in asthma DOI Creative Commons
Boudewijn J.H. Dierick,

Amber A. Eikholt,

Susanne J. van de Hei

et al.

Expert Opinion on Pharmacotherapy, Journal Year: 2024, Volume and Issue: 25(11), P. 1507 - 1516

Published: July 23, 2024

Introduction Asthma is a common disease with global burden of 358 million patients. Despite improvements in pharmacological and non-pharmacological treatments, many patients still do not achieve complete asthma control. Therefore, innovative pharmacotherapy important.

Language: Английский

Citations

2
New insights for the development of efficient DNA vaccines DOI Creative Commons
Simone Berger, Yanira Zeyn, Ernst Wagner

et al.

Microbial Biotechnology, Journal Year: 2024, Volume and Issue: 17(11)

Published: Nov. 1, 2024

Abstract Despite the great potential of DNA vaccines for a broad range applications, ranging from prevention infections, over treatment autoimmune and allergic diseases to cancer immunotherapies, implementation such therapies clinical is far behind expectations up now. The main reason poor immunogenicity in humans. Consequently, improvement performance vivo required. This mini‐review provides an overview current state various strategies enhance immunogenic vaccines, including (i) optimization construct itself regarding size, nuclear transfer transcriptional regulation; (ii) use appropriate adjuvants; (iii) improved delivery, example, by careful choice administration route, physical methods as electroporation nanomaterials that may allow cell type‐specific targeting. Moreover, combining nanoformulated with other immunotherapies prime‐boost help success treatment.

Language: Английский

Citations

2